Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

被引：0
|
作者：
Nielsen, Katrine Finderup [1 ,4 ]
Nielsen, Lise Birk [1 ]
Dalby, Tine [1 ]
Lomholt, Frederikke Kristensen [1 ]
Slotved, Hans-Christian [1 ]
Fuursted, Kurt [1 ]
Harboe, Zitta Barrella [1 ,2 ,3 ]
Jorgensen, Charlotte Svaerke [1 ]
Valentiner-Branth, Palle [1 ]
机构：
[1] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen, Denmark
来源：
EMERGING INFECTIOUS DISEASES | 2024年 / 30卷 / 06期
关键词：
AGED; 65; ENGLAND; PNEUMONIA; PEOPLE; ADULTS; IMPACT; OLDER;
D O I：
10.3201/eid3006.230975
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >= 65 years of age as part of a vaccination program in Denmark during Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
引用
收藏
页码：1164 / 1172
页数：9
相关论文
共 50 条
  • [31] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [32] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [33] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [34] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Mikkelsen Malene B
    Husby Oyvind
    Molden Tor
    Mwaura David N
    Olsen Jens
    Kristensen Nanna V
    Vietri Jeffrey
    Cost Effectiveness and Resource Allocation, 21
  • [35] Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
    Breiman, RF
    Keller, DW
    Phelan, MA
    Sniadack, DH
    Stephens, DS
    Rimland, D
    Farley, MM
    Schuchat, A
    Reingold, AL
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) : 2633 - 2638
  • [36] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Remschmidt, Cornelius
    Harder, Thomas
    Wichmann, Ole
    Bogdan, Christian
    Falkenhorst, Gerhard
    BMC INFECTIOUS DISEASES, 2016, 16
  • [37] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    VACCINE, 2013, 31 (50) : 6011 - 6021
  • [38] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [39] Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan
    Nisar, Muhammad Imran
    Jehan, Fyezah
    Shahid, Shahira
    Ahmed, Sheraz
    Shakoor, Sadia
    Kabir, Furqan
    Hotwani, Aneeta
    Muneer, Sahrish
    Khalid, Farah
    Muhammad, Sajid
    Althouse, Benjamin M.
    Hu, Hao
    Whitney, Cynthia G.
    Ali, Asad
    Zaidi, Anita K. M.
    Omer, Saad B.
    Iqbal, Najeeha
    PLOS ONE, 2022, 17 (01):
  • [40] Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan
    Riaz, Atif
    Mohiuddin, Syed
    Husain, Sara
    Yousafzai, Mohammad Tahir
    Sajid, Muhammad
    Kabir, Furcian
    Rehman, Najeeb Ur
    Mirza, Waseem
    Salam, Basit
    Nadeem, Naila
    Pardhanh, Khatidja
    Khan, Khalid Mehmood A.
    Raza, Syed Jamal
    Arif, Fehmina
    Iqbal, Khalid
    Zuberi, Hassan Khalid
    Whitney, Cynthia G.
    Omer, Saad B.
    Zaidi, Anita K. M.
    Ali, Asad
    Sheikh, Salma
    Memon, Yasmin
    Siyal, Rehman
    Lohana, Heeramani
    Rizvi, Shaheen
    Murtaza, Ghulam
    Ejaz, Muzzamil
    Shah, Lal Mir
    Masood, Khalid
    Baig, Samra
    Ashafaque, Agha
    Ansari, Abdul H.
    Jabbar, Abdul
    Pushpa
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 80 : 28 - 33
12345